Related Experiment Video
Updated: Jun 20, 2026
08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Mycophenolate mofetil and calcineurin-inhibitor reduction: recent progress
Josep M Grinyó1, Josep M Cruzado
1Nephrology Department, Hospital Univeritari de Bellvitge, Idibell, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain. jgrinyo@bellvitgehospital.cat
Summary
Mycophenolate mofetil (MMF) with calcineurin inhibitors (CNIs) reduces rejection. Avoiding CNIs with MMF increases rejection risk, but CNI elimination may improve outcomes in some patients.
Area of Science:
- Nephrology
- Immunosuppression
- Transplantation
Background:
- Mycophenolate mofetil (MMF) combined with calcineurin inhibitors (CNIs) effectively reduces acute rejection rates in organ transplantation.
- MMF was initially expected to mitigate CNI-associated nephrotoxicity due to its immunosuppressive properties.
- However, complete avoidance of CNIs in MMF-based immunosuppression regimens has led to increased risks of acute and chronic rejection.
Purpose of the Study:
- To evaluate the impact of calcineurin inhibitor (CNI) elimination versus minimization in patients receiving mycophenolate mofetil (MMF) based immunosuppression.
- To assess the risk-benefit balance of different CNI strategies in kidney transplant recipients.
- To explore the potential of novel CNI-free immunosuppression protocols, such as MMF with belatacept.
Main Methods:
- Review of a recent meta-analysis on CNI elimination in MMF-treated patients with renal dysfunction.
- Analysis of outcomes associated with CNI minimization strategies combined with MMF.
- Consideration of emerging CNI-free immunosuppression approaches and monitoring tools.
Main Results:
- A meta-analysis indicated that CNI elimination in MMF-treated patients with progressive renal dysfunction may be linked to better outcomes, though further research is required.
- CNI minimization alongside MMF has demonstrated improvements in renal function and maintained a low risk of rejection, suggesting a favorable risk/benefit profile.
- MMF in combination with belatacept presents a potential future strategy for CNI-free immunosuppression.
Conclusions:
- While CNI elimination shows promise for specific patient groups, CNI minimization with MMF offers a balanced approach with improved renal function and low rejection rates.
- Future CNI-free strategies, such as MMF with belatacept, warrant further investigation.
- Advanced immunological risk assessment tools may be crucial for the successful implementation of CNI-sparing protocols.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...